-
Je něco špatně v tomto záznamu ?
Discovery and Evaluation of Extracellular MicroRNA Biomarkers in Plasma, Ascites, and Urine
L. Záveský, O. Slanař
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články
- MeSH
- ascites MeSH
- biologické markery MeSH
- cirkulující mikroRNA * MeSH
- krevní plazma chemie MeSH
- lidé MeSH
- mikro RNA * genetika MeSH
- nádorové biomarkery MeSH
- následné studie MeSH
- tělesné tekutiny * metabolismus MeSH
- Check Tag
- lidé MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
MicroRNAs (miRNAs) comprise a large group of small noncoding RNAs within a heterogeneous entity of noncoding RNAs, forming potent functional tools regulating the crucial biological processes within cells and the body. Cell-free miRNAs have become one of the novel promising diagnostic, predictive, and prognostic biomarkers for various diseases extensively investigated in recent years. This is due to their presence within extracellular fractions of various body fluids suggesting their potential as noninvasive "liquid biopsy" in case of their dysregulated expression.Among the body fluids, blood plasma and serum along with urine are the most commonly investigated sources of various types of cell-free miRNAs. Another body fluid, i.e., ascites (effusion, peritoneal/pleural fluid) may be the clinically important fluid particularly associated with carcinogenesis in ovarian carcinomas and hepatocellular carcinomas or in case of liver cirrhosis.Here, we provide a protocol for an expression profiling study based on qPCR analyses aimed at finding novel candidate miRNAs via small-scale or large-scale screening and evaluation experiments using liquid biopsies of blood plasma, ascites, and urine. Using this approach may be worth in cases where no (or limited) information is available on miRNA expression in particular diseases and geographic regions, for validation of previously published miRNAs with promising diagnostic potential, particularly in situations where follow-up study is aimed at validating miRNAs coming from (micro) array or NGS experiments, or where funding for large-scale experiments is not available. We demonstrate that assessment of plasma, ascites, and urine miRNAs expression may represent a feasible method to explore the potential for finding novel diagnostic, predictive, and prognostic biomarkers for various diseases.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23004698
- 003
- CZ-PrNML
- 005
- 20230425171652.0
- 007
- ta
- 008
- 230418s2023 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/978-1-0716-2982-6_10 $2 doi
- 035 __
- $a (PubMed)36689181
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Záveský, Luděk $u Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University, Prague, and General University Hospital in Prague, Prague, Czech Republic. ludek.zavesky@lf1.cuni.cz $u Institute of Pharmacology, First Faculty of Medicine, Charles University, Prague, and General University Hospital in Prague, Prague, Czech Republic. ludek.zavesky@lf1.cuni.cz
- 245 10
- $a Discovery and Evaluation of Extracellular MicroRNA Biomarkers in Plasma, Ascites, and Urine / $c L. Záveský, O. Slanař
- 520 9_
- $a MicroRNAs (miRNAs) comprise a large group of small noncoding RNAs within a heterogeneous entity of noncoding RNAs, forming potent functional tools regulating the crucial biological processes within cells and the body. Cell-free miRNAs have become one of the novel promising diagnostic, predictive, and prognostic biomarkers for various diseases extensively investigated in recent years. This is due to their presence within extracellular fractions of various body fluids suggesting their potential as noninvasive "liquid biopsy" in case of their dysregulated expression.Among the body fluids, blood plasma and serum along with urine are the most commonly investigated sources of various types of cell-free miRNAs. Another body fluid, i.e., ascites (effusion, peritoneal/pleural fluid) may be the clinically important fluid particularly associated with carcinogenesis in ovarian carcinomas and hepatocellular carcinomas or in case of liver cirrhosis.Here, we provide a protocol for an expression profiling study based on qPCR analyses aimed at finding novel candidate miRNAs via small-scale or large-scale screening and evaluation experiments using liquid biopsies of blood plasma, ascites, and urine. Using this approach may be worth in cases where no (or limited) information is available on miRNA expression in particular diseases and geographic regions, for validation of previously published miRNAs with promising diagnostic potential, particularly in situations where follow-up study is aimed at validating miRNAs coming from (micro) array or NGS experiments, or where funding for large-scale experiments is not available. We demonstrate that assessment of plasma, ascites, and urine miRNAs expression may represent a feasible method to explore the potential for finding novel diagnostic, predictive, and prognostic biomarkers for various diseases.
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a mikro RNA $x genetika $7 D035683
- 650 _2
- $a ascites $7 D001201
- 650 _2
- $a následné studie $7 D005500
- 650 _2
- $a biologické markery $7 D015415
- 650 12
- $a tělesné tekutiny $x metabolismus $7 D001826
- 650 12
- $a cirkulující mikroRNA $7 D000074166
- 650 _2
- $a krevní plazma $x chemie $7 D010949
- 650 _2
- $a nádorové biomarkery $7 D014408
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Slanař, Ondřej $u Institute of Pharmacology, First Faculty of Medicine, Charles University, Prague, and General University Hospital in Prague, Prague, Czech Republic
- 773 0_
- $w MED00180389 $t Methods in molecular biology (Clifton, N.J.) $x 1940-6029 $g Roč. 2630, č. - (2023), s. 135-143
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/36689181 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230418 $b ABA008
- 991 __
- $a 20230425171648 $b ABA008
- 999 __
- $a ok $b bmc $g 1925031 $s 1190907
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 2630 $c - $d 135-143 $e - $i 1940-6029 $m Methods in molecular biology $n Methods Mol Biol $x MED00180389
- LZP __
- $a Pubmed-20230418